What research says about GLP-1 and the thyroid
GLP-1 medications like semaglutide and tirzepatide work by mimicking an intestinal hormone that controls appetite. Early clinical trials included warnings about possible thyroid risk, particularly for people with a personal or family history of medullary thyroid carcinoma.
Those warnings came from rodent studies where the medications caused thyroid C-cell tumors. In humans, the picture is different. A review published in Thyroid Research (2021) found no significant increase in thyroid cancer rates among semaglutide users compared to the general population. That said, doctors remain cautious and often recommend baseline thyroid testing before starting treatment in high-risk patients.
For people already managing hypothyroidism with medication, existing evidence suggests GLP-1 use does not worsen thyroid function. What sometimes happens is that the weight loss resulting from treatment can improve TSH levels, which is the marker used to assess how well the thyroid is working.